Abstract To test the hypothesis that hepatic cholesteryl ester is involved in the regulation of apolipoprotein (apo) B secretion into plasma, apoB kinetic studies were performed in six control miniature pigs and in six pigs after a 21-day administration of the acyl coenzyme Axholesterol acyltransferase (ACAT) inhibitor DuP 128 (2.2 mg • kg" 1 • d" 1 IV). Pigs were fed low-fat, cholesterol-free diets. Total plasma cholesterol, triglyceride, very-low-density lipoprotein (VLDL) triglyceride, and low-density lipoprotein (LDL) cholesterol decreased 18%, 29%, 40%, and 26% respectively (P<.03).
I-LDL were injected simultaneously into each animal, and apoB kinetics were analyzed by using multicompartmental analysis (SAAM30). VLDL apoB pool size decreased significantly by 60% (0.32 versus 0.84 mg/kg), which was due to a 65% reduction in the VLDL apoB production or secretion rate (1.03 versus 2.94 mg • kg" 1 • h" 1 ). The fractional catabolic rate was unchanged. LDL apoB pool size decreased nonsignificantly by 18% (5.61 versus 6.90 mg/kg) due entirely A polipoprotein (apo) B-100 is required for the / \ assembly and secretion of apoB-containing li-J. A-poproteins from the liver, which transport both triglyceride and cholesteryl ester. 1 ApoB represents approximately 30% to 45% of total very-low-density lipoprotein (VLDL) apoproteins and over 90% of lowdensity lipoprotein (LDL) apoproteins. In the hepatocyte, apoB-containing lipoproteins are assembled in the endoplasmic reticulum (ER), modified in the Golgi apparatus, and subsequently secreted into plasma. 24 Regulation of the assembly and secretion of hepatic apoB-containing lipoproteins has received considerable attention due to the widely accepted view that overproduction of these lipoproteins is the mechanistic basis for many of the hyperlipidemia syndromes. 49 Familial combined hyperlipidemia and/or hyperapobetalipoproteinemia are characterized by an overproduction of hepatic apoB-containing lipoproteins, and subjects with such conditions are at increased risk for the development of atherosclerosis. 10 -11 The regulation of hepatic apoB secretion at the level of apoB transcription is not clear. Some evidence indi-However, in monkeys 19 and mice 20 fed lipogenic diets and in HepG2 cells treated with 25-hydroxycholesterol, 21 hepatic apoB mRNA is increased. Hepatic apoB-containing lipoproteins destined for secretion contain triglyceride, both free and esterified cholesterol, and phospholipids. It has been proposed that the availability of triglyceride, cholesterol, and cholesteryl ester regulate the posttranslational metabolism of apoB and hence its secretion rate. 22 - 25 Under basal conditions in HepG2 cells 2426 and in primary rat 22 and rabbit 27 hepatocytes, a significant portion of nascent apoB is degraded intracellularly, most likely in the ER 23, 26 However, whether this occurs in vivo is not known. In HepG2 cells, exogenous fatty acids lead to enhanced triglyceride synthesis, which stimulates apoB secretion by protecting apoB from the degradation pathway. 2425 This does not appear to be the case in primary rat hepatocytes, in which triglyceride but not apoB secretion is enhanced by oleate. 28 However, oleate stimulates both triglyceride and apoB secretion from perfused livers from fasted rats. 29 In primary hamster hepatocytes, stimulation of triglyceride synthesis does not enhance apoB secretion, but secretion is decreased when triglyceride synthesis is inhibited. 30 The availability of cholesterol or cholesteryl ester regulates hepatic apoB secretion. Synouri-Vrettakou et al 31 have proposed that there are several cellular cholesterol pools, a metabolically active pool of free cholesterol, a free cholesterol pool that is substrate for the cholesterol-esterifying enzyme (acyl coenzyme Axholesterol acyltransferase [ACAT]), and a cholesteryl ester pool. Lange et al 32 have provided evidence that the ACAT substrate pool is in rapid equilibrium with the plasma membrane cholesterol pool.
In vivo apoB kinetic studies have provided indirect evidence that reduction of hepatic cholesterol synthesis reduces apoB secretion into plasma. Dietary cholesterol increases apoB secretion in perfused rat liver, 33 and in miniature pigs treatment with a hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitor decreases apoB production. 3435 Similar findings have been reported in patients with primary hypercholesterolemia, 36 combined hyperlipidemia, 7 and cholesteryl ester storage disease. 37 However, this finding is not universal 38 and was not found in patients with familial hypercholesterolemia. 7 The availability of hepatic cholesteryl ester may play a role in the regulation of apoB secretion, indicating a link between liver ACAT activity and the secretion of apoB-containing lipoproteins. Cianflone et al 39 have shown that treatment of oleate-stimulated HepG2 cells with the ACAT inhibitor SH 58-035 reduces apoB secretion by 25%. Incubation of cholesterol-loaded primary rabbit hepatocytes with an HMG CoA reductase inhibitor also reduces apoB secretion, a process correlated with a reduction in cellular cholesteryl ester content. 27 Treatment of experimental animals with ACAT inhibitors lowers plasma cholesterol and apoB concentrations, but mainly in animals that are fed diets containing high amounts of cholesterol. 4046 Most studies have concluded that the mechanism responsible for plasma cholesterol lowering in animals treated with ACAT inhibitors is due to inhibition of absorption secondary to ACAT inhibition in the intestinal mucosal cell. Few studies have been designed to determine whether the regulation of apoB secretion by hepatic ACAT activity could account for some of the effects of ACAT inhibitors in vivo. Krause et al 47 have demonstrated that the ACAT inhibitor CI-976 lowers plasma cholesterol, LDL cholesterol, and apoB in rabbits fed a cholesterol-free casein-based diet, an animal model characterized by an overproduction of hepatic apoBcontaining lipoproteins. 48 Perfused livers from cholesterol-fed monkeys treated with CI-976 secrete less cholesteryl ester and apoB compared with cholesterol-fed controls. 49 Cholesterol-fed rats treated with CI-976 subcutaneously have lower plasma cholesterol concentrations relative to cholesterol-fed controls, suggesting that liver ACAT may play a role. 40 In the present studies, the ACAT inhibitor DuP 128 was used to test the hypothesis that inhibition of hepatic cholesterol esterification in vivo in miniature pigs fed a cholesterol-free diet would reduce the secretion of apoB-containing lipoproteins into plasma. DuP 128, a potent noncompetitive inhibitor of ACAT, 5051 was given intravenously to maximize hepatic uptake. ApoB secretion was measured after the injection of autologous radioiodinated VLDL and LDL.
Methods Animals
Miniature pigs weighing between 22 and 30 kg were obtained from a local supplier (Hyde Park Farms). After acclimatization for 1 week, an indwelling silicone elastomer (Silastic) catheter (0.078-inch internal diameter) was surgically implanted in an external jugular vein. 35 Halothane was used as the anesthetic and ketamine as the preanesthetic. Catheters, which were kept patent by filling with 7% EDTA-Na 2 , allowed for ease of sample injection as well as blood sampling throughout each turnover study in unrestrained, unanesthetized animals. Six animals received 50 mg/d of the ACAT inhibitor DuP 128 (DuPont Merck Pharmaceutical Co) for 14 days prior to the turnover study.
is a noncompetitive inhibitor of ACAT with an in vitro IC 50 of 10 nmol/L for rat liver microsomal ACAT activity. 5051 The chemical structure of DuP 128 is shown in Fig 1. The drug (50 mg) was dissolved in 1.5 mL 95% ethanol, and then 0.5 mL propylene glycol (British Drug House, BDH), 2 mL polyethylene glycol 400 (BDH), and 1 mL sterile water were added; the resulting mixture was vortexed. The dose was given as an intravenous bolus into the indwelling catheter. Six control animals received the vehicle alone. The drug was given at 10 AM each day after a 16-hour fast. Each pig then received its daily ration of pig chow (750 g/d; Shur-Gain), which contained 16% protein, 5% fat (wt/wt), and no cholesterol. Animals were studied in pairs (one control and one experimental), with each pair being littermates. The experimental protocol was approved by the Animal Care Committee of the University of Western Ontario.
Lipoprotein Turnover Studies
Lipoprotein turnover studies were performed essentially as described.
-
53 Plasma (100 to 150 mL) was obtained after a 16-hour fast for isolation of VLDL (S f 20 to 400) and LDL (S t 0 to 12), which were subsequently radiolabeled with 131 I and 125 I, respectively. All labeled lipoproteins were autologous. Radiolabeling was performed by using the iodine monochloride technique. 53 Lipoproteins were sterilized by the addition of gentamicin sulfate (100 fig/mL ) and checked for pyrogenicity and sterility. Of the total VLDL radioactivity, less than 2% was free iodine, 25% to 35% was bound to lipid, and 24% to 37% of the protein-bound label was bound to apoB. Of the total LDL radioactivity, less than 1% was free iodine, 25% to 30% was bound to lipid, and 80% to 90% of the protein-bound label was bound to apoB. After a 16- 
Kinetic Analysis
The turnover data were analyzed by using the multicompartmental modeling program CONSAM 56 running on a 486 PC. The model chosen to describe the data was simultaneously fit to the two sets of tracer data for all lipoprotein fractions. This approach permits the integration of all tracer data into a single model. Since the two tracers were introduced into two different lipoprotein fractions, the information contained in each data set helped support different aspects of the model structure. Fig 2 shows the compartments of the model and the pathways that connect the compartments within and between lipoprotein fractions. Plasma VLDL apoB kinetic data are characterized by three compartments, designated compartments 1, 2, and 5. The sum of the specific radioactivities in each of these compartments equals the measured apoB specific activity of the VLDL fraction. Upon reinjection of the 131 I-labeled VLDL, it was assumed that apoB radioactivity distributed between the three compartments in proportion to their pool size; hence the apoB specific radioactivity in compartments 1, 2, and 5 were equal at the time of reinjection. Compartment 5, which represented most of the mass of the VLDL apoB fraction, turned over rapidly and accounted for the initial fall of the 131 I-VLDL apoB specific radioactivity curve. Compartment 2 turned over more slowly than compartment 5 by an order of magnitude. Compartment 1, which turned over more slowly than compartment 2, described the terminal slope of the 131 I-VLDL apoB radioactivity data. Plasma IDL apoB specific activity is characterized by two compartments, 3 and 4. Due to difficulty in obtaining accurate IDL apoB mass measurements, and because labeled IDL was not reinjected, it was assumed that all IDL apoB was derived from VLDL. The LDL section of the model is characterized by a plasma compartment, compartment 10, and an extravascuiar compartment, compartment 11. Although this assumes that LDL apoB is kinetically homogeneous, it is not possible to address the question of LDL heterogeneity without isolating LDL subfractions and/or collecting urine radioactivity data. Although 125 I-urine radioactivity data were collected in a previous study, 51 they were unusable due to high lipid labeling. It was assumed that at the time of reinjection all 125 I-LDL tracer was introduced into the plasma compartment. In addition, it was assumed that the irreversible loss of LDL apoB occurred only from compartment 10.
The model allows for the direct removal of apoB from plasma compartments 5, 2, 1, 4, and 3; movement from compartment 5 to 2 (VLDL), directly to 4 (IDL), and directly to 10 (LDL); movement from compartment 2 to 1 (VLDL), to 4 (IDL), and to 10 (LDL); and movement from 4 to 3 (IDL) and to 10 (LDL). Because compartments 1 and 3 turned over slowly (=0.1 h" 1 ) and represented only small proportions of the VLDL and IDL fractions, it was assumed that the material in these compartments was removed directly from plasma. In each of the studies, the terminal slopes of the VLDL and IDL specific activity curves were parallel; thus, the rate constants L(0,l) and L(0,3) were constrained to be equal.
During the course of each study, aliquots of plasma (taken at t=0) were spiked with a small aliquot of the 131 I-VLDL injected dose. Each spiked sample was then processed with the other plasma samples to determine the amount of radioactivity in apoB in the VLDL, IDL, and LDL fractions. For these studies, the average distribution of 131 I apoB radioactivity in the spiked samples was 88.5±4%, 10.0±2%, and 1.4+0.3% in the VLDL, IDL, and LDL fractions, respectively. Based on the distribution of radioactivity in the spiked samples, the initial conditions (the initial amount of radioactivity in each fraction) were incorporated into the compartmental model. This takes into account any contamination due to incomplete separation by ultracentrifugation and/or any alteration in the injected VLDL resulting in an increase in density during the in vitro preparation. The relative contribution cannot be determined. To test the effect of the LDL initial conditions, the data were analyzed by using a model in which the initial conditions were set at zero (at t=0). The results of this analysis were not compatible with the experimental data.
Liver Lipids
Lipids were extracted by using the method of Folch et al 57 from 1-g aliquots of liver that had been stored at -80°C.
[la,2a(n)- 3 H]cholesteryl oleate and glycerol tri[l-14 C]oleate (Amersham) were added to assess recovery. The chloroform phase was dried under nitrogen, resuspended in chloroform/ methanol (2:1, vol/vol), and separated by thin-layer chromatography on Fisherbrand silica gel G plates (Fisher Scientific) by using a petroleum ether/diethyl ether/acetic acid (84:15:1, vol/vol/vol) solvent system. A standard lipid mixture (Supelco) was used to identify free cholesterol, cholesteryl ester, and triglyceride on the thin-layer chromatography plates. The plates were dried in air, and the bands were visualized by exposure to iodine vapor. Samples were recovered from the gel with isopropanol, dried under nitrogen, and resuspended in 1.0 mL isopropanol. To each cholesterol and cholesteryl ester sample, 5a-cholestane was added as an internal standard, the solvent was evaporated under nitrogen, and the residue was saponified as described. 58 The mass of cholesterol and cholesteryl ester in each sample was determined by gas-liquid chromatography. 58 The triglyceride mass in each sample was then determined by using the method of Neri and Frings. 59 
Liver and Intestine ACAT Activity
Liver and intestine samples obtained at necropsy were stored at -80°C until assayed. Tissue samples were thawed and homogenized in 3 mL buffer per gram of tissue (0.1 mol/L phosphate buffer, pH 7.4, containing 0.5 mmol/L EDTA, 1 mmol/L glutathione, and 20 /imol/L leupeptin). Microsomes were prepared by differential centrifugation (lOOOg to 100 OOOg pellet). Microsomes for ACAT assays were resuspended in 0.1 mol/L phosphate buffer containing 1 mmol/L glutathione, and those for diacylglycerol acyltransferase (DGAT) were resuspended in 5 mmol/L Tris, pH 7.4, containing 0.25 mol/L sucrose. Microsomes (about 30 mg/mL) were frozen at -80°C until assayed. ACAT and DGAT activities were assayed according to the procedures of Billheimer et al 60 2 as described by Rustan et al, 61 respectively. Where added, DuP 128 was dissolved in dimethyl sulfoxide (5 fih per assay) with dimethyl sulfoxide alone added to control assays.
Analyses
Total cholesterol and triglyceride, VLDL cholesterol and triglyceride, and HDL cholesterol concentrations in plasma were determined. VLDL was obtained after ultracentrifugation at rf<1.006, 35 and HDL was obtained after precipitation of other lipoproteins by dextran sulfate-magnesium chloride. 35 LDL cholesterol was calculated by difference. Total cholesterol (CHOD-PAP C-system), triglyceride (triglyceride without free glycerol), free cholesterol (cholesterol-free test combination), and phospholipids (enzymatic colorimetric test combination) were determined by enzymatic analyses by using kits obtained from Boehringer-Mannheim. Lipoprotein protein was determined by the method of Markwell et al. 54 Tests for statistical significance of differences in lipid and apoprotein concentrations and the kinetic parameters during each treatment phase were compared by unpaired / test. 62 
Results
DuP 128 is a potent inhibitor of rat liver ACAT 50 and is an equally potent inhibitor of porcine liver ACAT, with an IC 50 of 2.5 nmol/L (Fig 3) . DuP 128 has no effect on porcine DGAT activity at concentrations as high as 80 /xmolfL (data not shown).
The effects of DuP 128 on plasma and lipoprotein lipid concentrations are shown in Table 1 . Total plasma and VLDL triglyceride concentrations were significantly reduced by 29% (P<.03) and 40% (P<.03), respectively. Total plasma cholesterol was reduced by 18% (P<.014). LDL cholesterol concentrations decreased by 26% (P<.001). The concentrations of HDL cholesterol were not altered by the ACAT inhibitor. DuP 128 significantly reduced the concentrations of VLDL apoB by 60% (P<.0002) and nonsignificantly reduced LDL apoB by 18%.
Autologous radiolabeled VLDL and LDL were simultaneously injected into each control pig and each pig treated with DuP 128. The kinetic parameters of apoB were determined from the simultaneous analysis of all specific activity data by using the model shown in Fig 2 . The kinetic parameters are summarized in Tables 2 and  3 . A fit of the model to the apoB specific radioactivity curves for 131 I in VLDL, IDL, and LDL for one representative animal is shown in Fig 4. In this model, approximately 90% of apoB enters the circulation as VLDL, about 10% of VLDL apoB flux is converted to LDL (either through the IDL pool or directly without passing through plasma IDL), and about 10% of apoB enters the circulation directly as LDL.
The intravenous administration of DuP 128 significantly reduced the pool size of VLDL apoB by 60% (Z'<.0004) ( Table 2 and Fig 5) . This was primarily due to a significant 65% reduction in the VLDL apoB production rate (F<.014), as the fractional catabolic rate was not altered. The decreased production rate of VLDL apoB was associated with a 65% (P<.03) decrease in the amount of VLDL apoB leaving the circulation directly (without conversion to IDL or LDL). Although the amount of VLDL apoB converted to LDL decreased by 46%, this was not statistically significant, indicating that there was a tendency for the fate of VLDL apoB to change with treatment. The percent of VLDL apoB flux that was converted to LDL tended to increase (12% versus 8%), whereas the percent cleared directly tended to decrease (80% versus 73%); however, these differences were not statistically significant. The model allowed us to determine the production or flux of VLDL apoB that was converted to LDL without being transported through the plasma IDL pool as well as the amount of VLDL apoB converted to LDL via the IDL fraction. The percentage of total VLDL apoB production that was either converted to LDL directly or converted to LDL via IDL did not change.
The kinetic parameters of LDL apoB are listed in Table 3 . DuP 128 reduced the LDL apoB pool size nonsignificantly by 18%. Mean values for total LDL apoB production were reduced by 23% by DuP 128, which was accounted for by a decrease in LDL apoB derived from VLDL apoB catabolism, but neither of these changes were significant. LDL apoB direct synthesis was not altered. The LDL apoB fractional catabolic rate was not changed by DuP 128 treatment (Table  3) as illustrated by the lack of difference in the LDL apoB specific activity curves between treatment and control animals (Fig 6) .
Three days after the kinetic study, plasma samples were obtained from eight animals (four control and four DuP 128), and VLDL was analyzed for lipids and protein. The percent composition did not change for any of the parameters measured (Table 4) . However, there was a trend for the percent triglyceride to increase and the percent cholesteryl ester to decrease with DuP 128 treatment. The surface/core lipid ratio also increased with treatment, suggesting a tendency to smaller particles.
Approximately 20 hours after the last dose of DuP 128 was administered, the pigs were killed, and segments of liver and small intestine were removed for LDL indicates low-density lipoprotein; ApoB, apolipoprotein B; and FCR, fractional catabolic rate. Pool size refers to the plasma LDL apoB concentration multiplied by 0.42, making the assumption that in the pig there are 42 mL plasma per kilogram body weight. 53 FCR is the rate constant L(0,10) determined from the model. Direct production (direct synthesis) is the production of apoB directly into compartment 10, U(10). There were no significant differences.
measurement of cholesterol and triglyceride content and ACAT and DGAT activity. The results (Table 5) indicate that the concentration of free cholesterol is unaltered by treatment with DuP 128. The liver cholesteryl ester content, which represented approximately 10% of the total liver cholesterol, was not affected by DuP 128. In addition, hepatic triglyceride concentrations were unaltered. The ACAT activity measured in hepatic microsomes is shown in Table 6 . DuP 128 significantly reduced ACAT activity by a mean of 68% (P<.0002). In some samples, ACAT activity was also measured in whole-liver homogenates as well as in microsomes that had been supplemented with exogenous cholesterol to optimize assay conditions. The same relative inhibition of activity by DuP 128 was observed (data not shown). ACAT activity was also measured in microsomes prepared from segments of small intestine (Table 6) , and although the mean activity was lower in the DuP 128-treated animals, this difference was not significant. Hepatic microsomal DGAT activity was not affected by DuP 128 treatment (Table 6 ).
Hours

Discussion
The inhibition of cholesterol synthesis with HMG CoA reductase inhibitors reduces apoB secretion into plasma, indicating a regulatory role for cholesterol. Our experiments were designed to test the hypothesis that in vivo hepatic synthesis of cholesteryl ester by ACAT contributes to the regulation by lipid of secretion of apoB-containing lipoproteins. In HepG2 cells, inhibition of ACAT activity with the inhibitor SH 58-035 reduces apoB secretion, 39 and the same inhibitor reduces both cholesteryl ester and apoB secretion from perfused monkey livers. 49 The inhibitor CI-976 lowered both cholesterol and apoB concentrations in a rabbit model of endogenous hypercholesterolemia, 47 which is characterized by a hepatic overproduction of apoB. 48 Taken together, these studies suggest that the availabil- Liver lipid values are milligrams per gram wet weight. Livers were removed approximately 20 hours after the last dose of DuP 128. Aliquots from several lobes of liver were excised and frozen at -80°C until analysis. Liver cholesterol and triglyceride concentrations were determined as described in "Methods." There were no significant differences.
ity of hepatic cholesterol and in particular hepatic cholesteryl ester influences the rate of hepatic apoB secretion.
This article provides direct in vivo evidence that inhibition of hepatic ACAT activity with the potent ACAT inhibitor DuP 128 at a dose of 2.2 mg • kg"
significantly reduces the secretion into plasma of apoBcontaining lipoproteins in pigs fed a cholesterol-free diet. VLDL apoB secretion was reduced by 60%, leading to a marked reduction in VLDL apoB pool size. LDL apoB pool size and the LDL apoB production rate were not significantly changed. The fractional catabolic rate of both VLDL and LDL apoB were not affected by ACAT inhibition. Despite a large reduction in VLDL apoB production, this did not translate into a reduction in the conversion of VLDL apoB to LDL or the LDL apoB pool size. VLDL composition data suggested a decrease in particle size with DuP 128. Smaller VLDL particles may be more readily converted to LDL, 63 which is consistent with the present kinetic results in that there was a tendency for an increase in the percent of total VLDL flux converted to LDL (8% to 12%) and a decrease in the percent of total flux cleared directly (80% to 73%).
ACAT inhibitors may have direct or indirect antiatherosclerotic effects at several tissue sites including intestine, liver, and the arterial wall. 65 However, many ACAT inhibitors are poorly absorbed and have low systemic availability. In general, the greater the dietary cholesterol content, the greater the plasma cholesterol lowering by these agents. Therefore, most studies have concluded that the mechanism responsible is inhibition of cholesterol absorption secondary to ACAT inhibition in the intestinal mucosal cell. 40 -4665 DuP 128 has limited oral bioavailability and therefore was administered intravenously to ensure the likelihood of observing any hepatic effect. The use of the intravenous route together with a low-fat, cholesterol-free diet minimized potential confounding effects of intestinal mucosal cell ACAT inhibition. The inhibition of intestinal ACAT after oral doses of ACAT inhibitors decreases mucosal cholesteryl esterification, cholesterol absorption, and chylomicron formation and secretion. 4046 A decreased delivery of chylomicron remnant cholesteryl ester to the liver would be expected to decrease the hepatic cholesterol and/or cholesteryl ester regulatory pool, thereby decreasing hepatic apoBcontaining lipoprotein secretion, an effect secondary to intestinal ACAT inhibition. After intravenous administration of DuP 128, we found that hepatic ACAT was inhibited by 68%, and the mean intestinal ACAT activity was reduced nonsignificantly by 38%. We cannot entirely rule out an intestinal effect of DuP 128. However, with the use of a low-fat, cholesterol-free diet, the contribution of dietary triglyceride and cholesterol from the intestine would be expected to be low. This supports the concept that reduction in apoB-containing lipoprotein secretion into plasma is directly related to the inhibition of hepatic ACAT rather than being secondary to intestinal ACAT inhibition. This idea is supported by Krause et al, 40 who show that subcutaneous dosing of the ACAT inhibitor CI-976 in casein-and sucrose-fed hypercholesterolemic rats significantly decreased plasma cholesterol and triglyceride concentrations. However, these authors did not measure apoB secretion rates nor hepatic ACAT activity.
Our findings that DuP 128 inhibited VLDL apoB secretion and lowered VLDL concentrations may be significant with respect to atherosclerosis. Bocan et al 65 found that in cholesterol-and fat-fed micropigs the ACAT inhibitor CI-976 reduced atherosclerotic lesion development, a finding that was highly correlated with a reduction in plasma VLDL concentrations.
There is considerable in vivo and in vitro evidence that stimulation of hepatic triglyceride synthesis stimulates apoB secretion, 4 ' 1618 -22 -25 -29 but this has not been a universal finding. 2830 The decreased secretion of apoBcontaining lipoproteins in the present study was due primarily to inhibition of hepatic cholesterol esterification and was not related to a decreased rate of triglyceride synthesis. At the dose of DuP 128 used, hepatic ACAT was inhibited by 68%, whereas DGAT activity was not affected. This enzyme catalyzes the final and unique step in triacylglycerol biosynthesis and is considered to be rate limiting. 66 In HepG2 cells in which triglyceride synthesis is stimulated with exogenous oleate, inhibition of ACAT with SH 58-035 results in a decrease in apoB secretion, but this is accompanied by an increase in intracellular triglyceride. 39 In the present study, the concentration of hepatic triglyceride was unchanged with DuP 128, suggesting that triglyceride was diverted to catabolic pathways, including those involving /3-oxidation.
There is evidence from studies in rat hepatocytes that active synthesis of phosphatidylcholine is absolutely essential for VLDL apoB secretion. 67 We did not measure the effect of DuP 128 on phospholipid synthesis in the present study. However, in previous experiments in human monocytes, concentrations of DuP 128 up to 100 /xmol/L (1400-fold the IC 50 for monocyte ACAT) did not decrease the incorporation of 3 H-oleoyl CoA into total phospholipids (P.J. Gillies, unpublished data, 1993) . Thus, it is unlikely that the decrease in VLDL apoB secretion with DuP 128 was secondary to an inhibition of phosphatidylcholine biosynthesis.
It is unlikely that cholesteryl ester alone is entirely responsible for the regulation of hepatic apoB secretion. Perfused rat liver studies suggest a coordinate role of triglyceride and cholesterol (or cholesteryl ester) in the assembly and secretion of apoB-containing lipoproteins. 433 Studies in HepG2 cells suggest that cholesteryl ester concentrations are sufficient to support apoB secretion at most levels of triglyceride synthesis. 4 The availability of cholesteryl esters may only become rate limiting under certain conditions. Wetterau et al 68 have provided evidence that if triglyceride and cholesteryl ester are unable to assemble with nascent apoB in the ER, then apoB secretion is severely limited. These authors propose that a microsomal lipid transfer protein is responsible for the translocation of triglyceride and cholesteryl ester to the apoB molecule. A mutation of this transfer protein is responsible for the inhibition of apoB secretion in human abetalipoproteinemia. 68 - 69 Venkatesan et al 70 have proposed that a stimulated transfer of triglyceride and cholesteryl ester to the apoB in the ER may be responsible for the overproduction of apoB-containing lipoproteins in patients with familial combined hyperlipidemia.
The mechanism whereby a reduction in hepatic ACAT activity leads to a decrease in apoB secretion is not clear. ApoB may be synthesized constitutively and be inserted into the ER membrane; if the apoB does not become associated with lipid, it is targeted for intracellular degradation. 2226 In HepG2 cells, stimulation of apoB secretion by oleate decreases the rate of intracellular apoB degradation. 25 Inhibition of hamster hepatocyte triglyceride biosynthesis increases the rate of intracellular apoB degradation. 30 Treatment of cultured rabbit hepatocytes with an HMG CoA reductase inhibitor decreases cellular cholesteryl ester concentrations and apoB secretion and increases intracellular apoB degradation. 27 Thus, in the present studies, the reduction of apoB secretion associated with hepatic ACAT inhibition may result in enhanced intracellular apoB degradation.
We were unable to demonstrate that the 68% reduction in hepatic ACAT activity decreased the hepatic cholesteryl ester concentration. The reason for this is not understood. In the livers of these pigs, ACAT inhibition in the ER presumably reduces cholesteryl ester in a small regulatory pool, a change that is not reflected in the concentration of the larger cholesteryl ester storage pool. Although it might be expected that ACAT inhibition would reduce the input of cholesteryl esters into the storage pool, it is possible that the cholesteryl ester pool in the ER, which is destined for association with apoB, is not tightly coupled to the cytoplasmic pool unless liver cholesterol flux is high. It should be pointed out that in the majority of animal studies in which the use of ACAT inhibitors reduced hepatic cholesteryl ester concentration, cholesterol flux was greatly elevated by either cholesterol feeding or models that induce an endogenous hypercholesterolemia. It is not known why a core lipid component that comprises less than 10% of the total composition affects VLDL apoB secretion. It is possible that some cholesteryl ester and triglyceride initially associate with newly synthesized apoB in the rough ER (RER), a process that is then critical for transfer to the smooth ER (SER) for further enrichment with triglyceride and thus lipoprotein formation. Studies in HepG2 cells suggest that apoB becomes associated with the RER membrane cotranslationally. 72 Some core cholesteryl ester may become associated with apoB at this stage as hepatic ACAT activity is located in the RER. 73 The primary neutral core lipid, triglyceride, is then added in the cisternae of the SER 72 to this partially lipidated apoB, and as the lipoprotein is formed it translocates to the ER lumen. 2 This concept is not completely consistent with the findings of Rusinol et al, 3 who showed that VLDL isolated from rat hepatic ER fraction I (probably RER), although low in concentration, has the same lipid composition as VLDL isolated from ER fraction II (SER). However, this does not exclude a role for cholesteryl ester in stabilizing apoB prior to acquiring the majority of its triglyceride.
It is not understood why the ACAT inhibitor decreased VLDL apoB secretion but had no effect on LDL "direct synthesis." One explanation is that the direct synthesis pathway accounts for only 10% of total apoB secretion. There may have been an effect on direct synthesis that was quantitatively too small to detect accurately. A second explanation is that ACAT inhibition selectively inhibited the secretion of VLDL-sized particles and not LDL-sized particles. Limitation of core cholesteryl ester for assembly with apoB in the ER (see above) may result in a nascent particle that is unable to acquire more triglyceride for particle enlargement but is still secreted as an LDL-sized particle. Testing of this hypothesis requires further in vitro studies. In previous studies 33 ' 34 our ability to show that HMG CoA reductase inhibitors inhibited "direct LDL" secretion may have been related to the reduced availability of total cholesterol for lipoprotein synthesis, thereby limiting cholesterol for both surface and core. Although it is possible that ACAT inhibition reduced the "direct synthesis" of IDL apoB, the experimental design did not allow us to test that possibility.
The inhibition of hepatic ACAT activity might also be expected to increase the free cholesterol concentration of the ER, leading to downregulation of LDL receptor expression. We found no increase in hepatic free cholesterol concentration and, importantly, no decrease in LDL apoB fractional catabolic rate was observed, suggesting that hepatic LDL receptor expression was unchanged. There is evidence that the ACAT substrate free cholesterol pool is distinct from the pool of cholesterol responsible for the regulation of the LDL receptor. 7475 Havekes et al 76 report that in HepG2 cells, LDL receptor expression is only partially responsive to increases in cellular free cholesterol, and there are reports that a decrease in hepatic ACAT activity is associated with an increased bile secretion of cholesterol and bile acids.
-
77
- 78 Although not measured in the present study, presumably free cholesterol accumulation was prevented by a decrease in HMG CoA reductase activity and increases in cholesterol 7a-hydroxylase activity and bile secretion.
In summary, this article provides the first in vivo kinetic evidence that hepatic ACAT plays a regulatory role in apoB secretion into plasma in the pig. Whether these findings are relevant to the treatment of human hyperlipidemia, such as familial combined hyperlipidemia, a lipid disorder characterized by an overproduction of apoB-containing lipoproteins, remains to be determined.
